Indeed. Ordinarily, Teva makes significant money from a generic drug only during the 180-day H-W exclusivity period. For Lovenox, however, the profits would continue indefinitely, and hence this amount is not chopped liver even for a company of Teva’s size.
The above amount still pales by comparison to what Teva earns from Copaxone, of course.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”